Consistent with this notion is our data showing that EGFR was activated by MUC1 in PTX-resistant cancer cells and more importantly, MUC1 inhibition resulted in diminished activity of EGFR and reduced expression of ABCB1 leading to reversal of PTX resistance. Here, ABCB1 is linked to cancer.